ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (FRA:R9Z)

Germany · Delayed Price · Currency is EUR

0.3840

+0.0140 (3.78%)

Last updated: Aug 26, 2026, 3:25 PM CET

-70.00% (1Y)

Market Cap	174.54M -67.3%
Revenue (ttm)	18.79M +108.1%
Net Income	-26.62M
EPS	-0.06
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,905
Open	0.3740
Previous Close	0.3700
Day's Range	0.3740 - 0.3840
52-Week Range	0.2940 - 1.7300
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 26, 2026

About FRA:R9Z

ImmuneOnco Biopharmaceuticals (Shanghai) Inc., a biotechnology company, engages in the research and development of immuno-oncology therapies in China and the United States. The company’s core product candidate is IMM01, which is in Phase Ib/IIa clinical trial to evaluate the combination with bortezomib and dexamethasone for the treatment of multiple myeloma; Phase II clinical trial in combination with azacitidine for the first-line treatment of higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia; and Phase III clinical tria... [Read more]

Industry Biological Products, Except Diagnostic Substances

Founded 2015

Employees 202

Stock Exchange Frankfurt Stock Exchange

Ticker Symbol R9Z

Financial Performance

In 2025, FRA:R9Z's revenue was 154.29 million, an increase of 108.09% compared to the previous year's 74.15 million. Losses were -218.58 million, -30.80% less than in 2024.

Financial numbers in CNY Financial Statements